跳到正文
原文
STAT Pharma 医药频道· Jonathan Wosen·· 11 天前AI 评分17

Ionis Pharmaceuticals 股价暴跌因 Tryngolza 销售不及预期

STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug

AI 导读

Ionis Pharmaceuticals 将 Tryngolza 今年销售额预期下调至 5000 万美元,远低于此前 1-1.1 亿美元的预期,第三季度销售额仅为 900 万美元,低于市场预期的 2100 万美元。股价应声下跌约 25% 至 28 美元。

正文

By Jonathan Wosen

Nov. 9, 2026

West Coast Biotech & Life Sciences Reporter

Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug the biotech and Wall Street analysts believe is a potential blockbuster. 

The firm announced that it expects the drug, Tryngolza, to bring in $50 million in sales by the end of this year, compared to Ionis’ previous forecast of $100 to $110 million. Third quarter sales came in at $9 million, well below Wall Street consensus expectations of $21 million during the quarter.

The stock reaction was swift. Shares that traded at more than $39 when the market opened within hours sank below $28, a drop of around 25%.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com